Table 1.
Baseline demographics and clinical characteristics of the RA patients included in the study
| RA patients (n = 23) | |
|---|---|
| Demographics | |
| Age, years | 52.6 (2.8)* |
| Gender, % female | 77 |
| Clinical characteristics | |
| Disease duration, years | 4.7 (1) |
| Rheumatoid factor and/or anti-CCP positive, % | 30 |
| Disease activity score in 28 joints | 6 (0.2) |
| Swollen (28) | 8.7 (1.2) |
| Tender (28) | 10.8 (1.7) |
| C-reactive protein, mg/dL | 2.4 (1.3) |
| Erythrocyte sedimentation rate, mm/h | 39.8 (7.3) |
| Treatments | |
| Naïve to treatment, n/total (%) | 13/23 (56 %) |
| Methotrexate, n/total (%) | 7/23 (30) |
| Methotrexate dose, mg/week | 17.1 (1.5) |
| Leflunomide, n/total (%) | 3/23 (13) |
| Biologic agents, n/total (%) | 4/23 (17) |
| Glucocorticoids, n/total (%) | 5/23 (22) |
| Glucocorticoid dose, mg/day | 8.2 (3.3) |
*Except where indicated otherwise, values are the mean (standard error of the mean). anti-CCP anti-cyclic citrullinated peptide